Premium
Vigabatrin
Author(s) -
Lewis Hilary,
Wallace Sheila J
Publication year - 2001
Publication title -
developmental medicine and child neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.658
H-Index - 143
eISSN - 1469-8749
pISSN - 0012-1622
DOI - 10.1111/j.1469-8749.2001.tb00172.x
Subject(s) - vigabatrin , epilepsy , clinical practice , medicine , partial epilepsy , refractory (planetary science) , psychology , psychiatry , anticonvulsant , family medicine , physics , astrobiology
The new antiepileptic drugs introduced over the last decade provide a welcome increase in the therapeutic options available for the 25% of children with epilepsy who remain refractory to traditional therapy. 1 In the mid 1980s, vigabatrin (VGB) was the first of these to be made available in clinical practice. In 1997, the visual field deficits reported in association with VGB prompted a review of its place in the management of epilepsy. We provide an overview of the uses of VGB and a discussion of the difficulties which currently affect our clinical practice.